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Abstract
Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and many novel
therapeutic approaches, average survival for the patients with malignant gliomas is only about 1 year. Tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) has shown potent and cancer-selective killing activity and drawn
considerable attention as a promising therapy for cancers, but concerns over delivery and toxicity have limited progress. We
have developed a secretable trimeric TRAIL (stTRAIL) and here evaluated the therapeutic potential of this stTRAIL-based
gene therapy in brain tumors. An adenovirus (Ad-stTRAIL) delivering stTRAIL was injected into intra-cranial human glioma
tumors established in nude mice and tumor growth monitored using the magnetic resonance imaging (MRI). Ad-stTRAIL
gene therapy showed potent tumor suppressor activity with no toxic side effects at therapeutically effective doses. When
compared with 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a conventional therapy for malignant gliomas, Ad-stTRAIL
suppressed tumor growth more potently. The combination of Ad-stTRAIL and BCNU significantly increased survival
compared to the control mice or mice receiving Ad-stTRAIL alone. Our data indicate that Ad-stTRAIL, either alone or
combined with BCNU, has promise as a novel therapy for malignant gliomas.
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Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is a member of the TNF family [1,2]. TRAIL is primarily
expressed as a type II transmembrane protein in which the
carboxyl terminus of the receptor-binding domain protrudes
extracellularly. Structural studies have demonstrated that biolog-
ically active soluble TRAIL forms a homotrimer [3,4]. This
homotrimeric structure of TRAIL is stabilized by a cysteine
residue at position 230 that coordinates with a divalent zinc ion
[4–6]. As the depletion of the zinc ion or a mutation of the cysteine
residue to alanine or glycine abrogates functional activity of
TRAIL [5,6], homotrimerization of TRAIL is pivotal for its
biological activity.
TRAIL acts through binding to its cognate receptors DR4 and/
or DR5 [7–9]. Once activated, DR4 and/or DR5 transmit
apoptotic signals intracellularly. Similar to other TNF family
members such as FasL and TNF-a, TRAIL activates caspase-8 as
an initial apoptotic signaling event [10,11]. Despite similarity in
apoptotic signaling cascades activated but the mechanism largely
unknown yet, TRAIL has a unique selectivity for triggering
apoptosis in tumor cells but not most normal cells [12,13]. In
addition, complying with the tissue distribution of the TRAIL
receptors, TRAIL has a wide range of targets. These features of
TRAIL have drawn considerable attention as a promising cancer
therapy [14].
Malignant gliomas are the most common brain tumors in adults
and account for more than half of all brain tumors [15,16].
However, treatment of malignant gliomas with conventional
approaches is largely unsuccessful because a wide resection
commonly applied for other malignancies is limited and curative
doses of therapeutics generally cannot be delivered to the tumor site
without excessive toxicity to normal tissues. As a consequence, the
mortality rate for the patients harboring malignant gliomas remains
high for the past decades. Here, we present a novel TRAIL-based
gene therapy for malignant gliomas. Our gene therapy approach
showed potent tumor suppressor activity for intracranial brain
tumor with no toxic side effects. Our data indicate that this
approach has great promise as a therapy toward malignant gliomas.
Results and Discussion
TRAIL is a membrane-bound ligand [1,2] which acts through
its cognate death receptors DR4 and/or DR5 on the surface of
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target cells [7–9,14]. It is thus expected that secreted soluble
TRAIL should kill a larger number of cells through wider
distribution. To develop a biologically active form of soluble
TRAIL produced in mammalian cells, we manipulated the
apoptosis-inducing moiety of TRAIL (amino acids 114–281) to
be secreted through fusion with a secretion signal sequence.
Interestingly, however, we observed that unlike recombinant
soluble TRAIL (114–281) produced from bacterial cells, the
secreted TRAIL (114–281) produced in mammalian cells
maintains its apoptotic functionality only when it is fused with a
trimerization-enforcing domain [17]. This result suggested that the
soluble TRAIL (114–281) ectopically expressed in mammalian
cells does not form the trimer quaternary structure required for
apoptotic activity [3,4,6]. Based on these observations, we have
created an expression cassette that encodes a secretable form of
trimeric TRAIL (stTRAIL) composed of the three functional
elements including a secretion signal, a trimerization domain and
an apoptosis-inducing moiety of TRAIL gene sequence
(Figure 1A). The stTRAIL is expressed as a pro-protein (SS-
ILZ-TRAIL) and converted to an active protein (ILZ-TRAIL)
following a specific cleavage by Furin [18], a protease residing in
Golgi complex, in the process of secretion.
In an attempt to establish a gene therapy approach to deliver
stTRAIL to tissues efficiently, we inserted our stTRAIL expression
cassette to Y5 [19], an E1/E3- doubly deleted human adenovirus
type 5 (Figure 1B). We compared apoptotic activity of Ad-stTRAIL
with that of an adenoviral vector (Ad-flTRAIL) carrying membrane-
bound full-length TRAIL (flTRAIL) in a trans-well system that allows
only soluble and diffusible agents to reach target cells. Ad-flTRAIL
showed no observable cell death, whereas Ad-stTRAIL effectively
induced death in the U87-MG target cells (Figure 1C). Ad-stTRAIL
also induced higher apoptotic activity than Ad-flTRAIL (data not
shown). Our data indicate that stTRAIL is diffusible and induces
death in cells remote from the site of production whereas membrane-
bound full-length TRAIL does not.
We then evaluated the potential of Ad-stTRAIL as a therapeutic
for gliomas in vitro and in vivo. In tests using various glioma cells
(Figure 2A), Ad-stTRAIL induced cell death in all except U373-MG
and ACBRI371, both of which also showed significant resistance to
recombinant TRAIL protein. Despite their resistance to TRAIL
Figure 1. Construction of Ad-stTRAIL and Tests of stTRAIL Secretion. (A) Schematic drawing of the stTRAIL expression cassette. (B)
Schematic drawing for constructing Ad-stTRAIL. An E1/E3-doubly deleted replication-incompetent adenoviral vector Ad-stTRAIL was constructed
through Cre-lox recombination. (C) Trans-well analysis. U373-MG cells were infected with adenovirus for 6 hours, washed two times with HBS and
transferred to the upper wells. U87-MG cells maintained at the bottom wells were co-cultured for 3 days with the upper wells and subjected to cell
viability assay. rhTRAIL was used as a positive control. The results represent the mean and SE for five separate experiments.
doi:10.1371/journal.pone.0004545.g001
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Figure 2. In vitro and in vivo Tumoricidal Activity Assessment of Ad-stTRAIL. (A) Glioma cells, plated in 24-wells, were treated with rhTRAIL
(0,100 ng/ml) or Ad-stTRAIL (1,100 MOI) and incubated for 48 h, followed by cell viability analysis as described in Materials and Methods. The
results represent the mean for five separate experiments. The SE bars were omitted, but were,5% at all the data points. (B) Better tumor suppressor
activity by divided low-dosed multiple delivery of Ad-stTRAIL. 16106 U87-MG cell were implanted to the left flank of 6-week-old SCID mice (Jackson
Laboratory) and treated with saline control or different modalities. To compare a single high-dose injection versus divided low-dosed multiple
injections in tumor suppressor activity, Ad-stTRAIL was delivered as indicated by arrows (n = 5 for each experimental group; total n = 20). The results
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(recombinant TRAIL protein or Ad-stTRAIL), U373-MG and
ACBRI371 cells expressed TRAIL receptors DR4 and DR5 (data
not shown). Moreover, all the cell lines also well expressed CAR, an
adenovirus receptor molecule. Thus, resistance of U373-MG and
ACBRI371 to Ad-stTRAIL seems unlikely to be associated with
efficiency of adenovirus infection. Currently, resistance of U373-
MG cells to TRAIL is under investigation.
In an animal tumor model established by subcutaneous injection
of U87-MG cells derived from human glioblastoma multiform, Ad-
stTRAIL (single injection of 161012 or six injections of 161011 virus
particles) also significantly suppressed tumor growth (Figure 2B).
The six injections more effectively suppressed tumor growth than
the single injection using a higher dose. In fact, multiple delivery of
Ad-stTRAIL to tumors resulted in sustained increase in stTRAIL
levels in the tumor injection site (Figure 2C).
Based on these promising results, we then sought to determine
the therapeutic efficacy of Ad-stTRAIL in a murine glioma model.
To establish a human glioma model, nude mice were injected
intra-cranially with varying numbers of U87-MG cells. We
identified that injection of 16105 cells/brain produces the most
appropriate animal model in terms of tumor growth, size and
animal longevity (Figure 3). Thus, throughout our studies to
evaluate therapeutic efficacy of Ad-stTRAIL, we used this animal
brain tumor model.
First, to assess therapeutic efficacy of Ad-stTRAIL, we delivered
Ad-stTRAIL at day 6 and 9 into the tumor site and monitored
tumor growth in live animals using MRI (Figure 4A, B, C). MRI
analysis showed no tumor growth in either the control or the
modality-treated groups during first 25 days. At day 32, however,
the control groups (saline and Ad-Y5) showed significant tumor
growth, while the modality-treated groups exhibited no growth. In
fact, even at day 70 after the delivery of Ad-stTRAIL, no tumors
were detectable in the modality-treated groups (Figure 4D).
Next, we evaluated side effects of Ad-stTRAIL in animals. We
followed the guideline of Korea Food and Drug Administration
(KFDA) for the development of new drugs. Accordingly, we used
normal rats and measured side effects after injecting various doses
of Ad-stTRAIL to the putamen region of rat brain. We first
determined the lethal dose of Ad-stTRAIL. As shown in Table 1,
rats tolerated all doses of Ad-stTRAIL tested. Therefore, the lethal
intracranial dose in rats is higher than 361010 viral particles per a
single injection. No change in body weight over time was observed
with injections of 36109 and 161010 viral particles, while the
highest dose gave rise to a transient decline in body weight
(Figure 5), which recovered after one week in both male and
female rats. Delivery of the same doses of Ad-stTRAIL to the
brains of normal mice did not significantly affect body weight (data
not shown). More importantly, when the same doses of viral
particles were directly delivered to tumors implanted in brains of
mice, no apparent side effects, including loss of body weight,
decreased food and water consumption, coughing, nasal discharge
and hunched posture, were observed (data not shown). Our data
indicate that administration of therapeutic doses of Ad-stTRAIL
injected into either normal brains or brain tumors is safe with no
apparent side effects.
To avoid any unwanted systemic toxicity, we consider only
intra-tumoral delivery of Ad-stTRAIL as a potential therapeutic
approach. It is important to know if the intra-cranially delivered
viral particles cross the blood-brain barrier to enter the blood
circulation resulting in possible systemic exposure. To address this
question, we analyzed viral DNA in blood plasma and multiple
organs at different time points following delivery of Ad-stTRAIL
(161010 viral particles) to rat brain. Detectable DNA peaked in the
blood at 30 min and then rapidly disappeared (Figure 6A).
Similarly, viral DNA was detectable in organs during only early
time points (Figure 6B). Although viral DNA was detected in the
blood circulation and organs, it is important to point that the
amount of viral DNA measured outside of the brain, even at the
peak, was just 0.0008% of the total input. Minimal stTRAIL
protein was detected in the blood plasma and liver (data not
shown). Thus, the quantity of viral particles and recombinant
protein that transiently enters the systemic circulation after brain
injection appears to be very limited. In contrast, viral DNA at the
injection site persisted longer (Figure 6C) and both DNA and
protein at the injection site correlated with the dose of viral
particles (Figure 6D). In addition to the blood plasma, we also
examined the viral particles in circulating blood cells including red
blood cells and lymphocytes. No significant amount of viral DNA
was observable in these cells (data not shown). Our data indicate
that Ad-stTRAIL cannot freely cross the blood-brain barrier and
remains localized mainly at the delivery site, where the expression
is sustained without systemic side effects.
We next compared the efficacy of Ad-stTRAIL with BCNU, a
conventional therapy for malignant gliomas which crosses the
blood-brain barrier. Although widely used for brain tumors,
BCNU only moderately limited growth of glioma cells in vitro
(Figure 7A). Compared to Ad-stTRAIL in vivo, BCNU was less
effective in suppressing tumor growth (Figure 7B, C). Tumor tissue
analysis after treating with BCNU or Ad-stTRAIL showed that
Ad-stTRAIL was associated with more TUNEL positive cells than
BCNU (Figure 7D).
represent the mean for the tumor volume. The SE bars were omitted, but were ,5% at all the data points. There were statistically significant
difference between any of two groups (P,0.05). (C) The expression profile of stTRAIL protein by multiple delivery of Ad-stTRAIL. When the tumor
diameter reached 6,8 mm after implanting U87-MG cells as described in (A), Ad-stTRAIL (161012 VP) was delivered once, twice or three times at 7-
day intervals. Tumor tissues were isolated and subjected to analysis of stTRAIL protein. The results represent the mean from three mice used for each
experimental group. The SE bars were omitted, but were ,5% at all the data points.
doi:10.1371/journal.pone.0004545.g002
Figure 3. Establishment of an Animal Brain Tumor Model.
Various number of U87-MG cells were stereotactically implanted to the
right striatum of the athymic mice (n = 6 for each experimental group;
total n = 24). A burr hole was drilled in the skull lateral to the bregma
and Hamilton syringe (22 G) was introduced to a depth of 3 mm.
Survival was examined and plotted.
doi:10.1371/journal.pone.0004545.g003
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Generally, combination therapies yield better efficacy with
fewer side effects, hence combination therapies are widely used in
cancer treatment. We therefore evaluated the combination of Ad-
stTRAIL and BCNU, in vitro and in vivo. BCNU modestly
enhanced the apoptotic activity of Ad-stTRAIL in TRAIL-
susceptible glioma cells including U87-MG, LN-18 and U343-
MG (Figure 8). In contrast, BCNU significantly augmented cell
death induced by Ad-stTRAIL in U373-MG and ACBRI371
(Figure 8), two tumor cell lines shown to be almost completely
resistant to Ad-stTRAIL or TRAIL protein alone (Figure 2).
Therefore, the combination of Ad-stTRAIL with BCNU broadens
the range of tumor cells responsive to therapy. Finally, we
evaluated therapeutic feasibility of Ad-stTRAIL/BCNU combi-
nation therapy in vivo (Figure 9). Ad-stTRAIL/BCNU combina-
tion therapy showed better tumor suppressor activity than Ad-
stTRAIL individual therapy (Figure 9B). Ad-stTRAIL/BCNU
combination therapy also improved the survival rate (Figure 9C).
These results raise the possibility that combination therapy would
be an effective strategy to treat even BCNU-resistant tumors.
Here, we demonstrate the therapeutic potential of a TRAIL-
based gene therapy approach utilizing a construct designed to
deliver a secretable form of trimerized TRAIL using a vector
system for local delivery. Ad-stTRAIL vector showed better
efficacy in an animal brain tumor model than BCNU. Combina-
tion therapy comprising Ad-stTRAIL and BCNU resulted in
greater efficacy than Ad-stTRAIL or BCNU alone. Furthermore,
Ad-stTRAIL was safe at the dose showing therapeutic efficacy. It is
important to note that repeated intracranial injection of Ad-
stTRAIL did not induce detectable anti-adenovirus immune
responses. In fact, no neutralizing anti-adenovirus antibody was
detectable in the plasma following repeated intracranial injection
of Ad-stTRAIL (data not shown), suggesting that expected
therapeutic efficacy can be obtained even after repeated delivery
of Ad-stTRAIL. Although the mechanism for limited host immune
Figure 4. Evaluation of Ad-stTRAIL as a Therapy for Gliomas. (A, B, C) The schematic drawing for experimental design and MRI analysis. U87-
MG human malignant glioma cells (16105 cells/10 mL per mouse brain) were stereotactically implanted into the right striatum of athymic mice (nu/
nu). 6 and 10 days after tumor implantation, controls (saline or Ad-Y5) or Ad-stTRAIL were delivered intra-tumorally. Tumor growth was monitored
by MRI at the indicated times. (D) Representative animals treated with Ad-Y5 or Ad-stTRAIL.
doi:10.1371/journal.pone.0004545.g004
Table 1. Mortality and Determination of the Lethal Dose.
Sex
Group/Dose
(VP/head)
No. of
animals Day after treatment
Mortality
(dead/total)
Approximate lethal
dose (VP/head)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Male Control 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% (0/6) Higher than 361010
36109 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% (0/6)
161010 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% (0/6)
361010 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% (0/6)
Female Control 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% (0/6) Higher than 361010
36109 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% (0/6)
161010 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% (0/6)
361010 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0% (0/6)
The control (the formulation buffer) or the modality (36109, 161010 or 361010 viral particles) at 30 ml/head was delivered to the putamen region of rat brain as
described in Materials and Methods and mortality was examined.
doi:10.1371/journal.pone.0004545.t001
Figure 5. Safety Assessment of Ad-stTRAIL in Animals. (A, B) Body weight changes in rats. The control (virus formulation buffer) or the
modality (36109, 161010 or 361010 viral particles) was delivered to the putamen region of rat brain and body weights were measured at the
indicated times (n = 6 for each experimental group; total n = 48). The results represent the mean and SE.
doi:10.1371/journal.pone.0004545.g005
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responses to Ad-stTRAIL remains to be determined, the blood-
brain barrier (BBB), separating the adenovirus-injection site from
the blood circulation, seems likely to play a certain role. Taken
together, our results raise the possibility that Ad-stTRAIL will be
effective in other chemo-resistant tumors and serve as the basis for
a clinical trail currently planned for malignant gliomas in Korea.
Materials and Methods
Reagents
Recombinant human TRAIL (rhTRAIL) was obtained from
R&D systems (Minneapolis, MN). BCNU (Carmustin) was
purchased from Sigma (St. Louis, MO). Antibodies against
monoclonal human TRAIL was purchased from PeproTech
(Rocky Hill, NJ).
Cell culture
U87-MG, T98G, U373-MG, SG388, and LN-18 cells,
originally obtained from American Type Culture Collection
(ATCC) (Rockville, MD), were cultured in MEM, MEM, MEM,
DMEM and DMEM, respectively. ACBRI371 cells, obtained
from Cell Systems (Kirkland, WA), were maintained in DMEM.
U343-MG cells, obtained from Dr. Chae-Ok Yun (Yonsei Cancer
Center Hospital, Korea), were cultured in DMEM.
Preparation of adenoviral vectors
An E1/E3-doubly deleted replication-incompetent adenoviral
vectors Ad-stTRAIL or Ad-flTRAIL was constructed through
Cre-lox recombination as described [20]. Ad-Y5 or Ad-flTRAIL
propagated on 293 cells (ATCC) was purified by cesium chloride
density gradient centrifugation and subsequent dialysis against
Tris-saline buffer (0.14 M NaCl, 0.7 mM Na2HPO4, 0.025 M
Tris, adjusted with HCl to pH 7.2). Ad-stTRAIL propagated on
293F cells (Invitrogen, USA) was purified using anion exchange
chromatography and immobilized metal affinity chromatography.
The purified virus was subsequently dialyzed against formulation
buffer (10 mM Tris (pH 7.5), 75 mM NaCl, 5% (w/v) sucrose,
0.02% (v/v) Tween-80, 1 mM MgCl2, 100 mM EDTA, 0.5% (v/
v) Ethanol and 10 mM L-Histidine). All viruses were kept at
280uC until use.
Trans-well analysis
U373-MG cells were infected with adenovirus for 6 hours and
transferred to the upper wells (Polycarbonate membrane 24 well,
Figure 6. Tissue Distribution of Ad-stTRAIL in Animals. (A, B) Ad-stTRAIL (161010 viral particles) was delivered to the putamen region of rat
brain and subjected to analysis at the indicated times for Ad-stTRAIL DNA copies in blood plasma (A) and in different organs (B). The results represent
the mean and SE for six separate experiments. (C) Ad-stTRAIL (36109, 161010 or 361010 viral particles) was delivered to the putamen region of rat
brain and analyzed at the indicated times for Ad-stTRAIL DNA copies in the injection site. The results represent the mean and SE for six separate
experiments. (D) After delivery of Ad-stTRAIL (161010 viral particles) to the putamen region of rat brain as described in (B), stTRAIL protein in the
injection site was analyzed at the indicated times. The results represent the mean and SE for six separate experiments.
doi:10.1371/journal.pone.0004545.g006
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0.4 mm pore, Corning) following two washes with HBS. U87-MG
cells maintained at the bottom wells were co-cultured with the
upper wells. Three days later, cell viability of U87-MG was
analyzed by MTS assay using the MTS assay kit purchased from
Promega (Madison, WI). rhTRAIL was used as a positive control.
In vitro treatment with BCNU
ACBRI371, U87-MG, U373-MG, U343-MG or LN-18 cells,
plated in 24-wells (16105 cells/well) in complete medium, were
incubated with different concentration of BCNU (50, 100, 250 or
500 mM). Three days after incubation, cells were processed for the
analysis of cell viability.
Cell viability assays
Cells infected with adenoviral vectors or treated with rhTRAIL
as a positive control were analyzed by MTS assay.
Animal experiments for efficacy assessment
Athymic mice (nu/nu) were purchase from Charles River
(Wilmington, MA) through a Korean distributor Orient Co., Ltd.
To generate an orthotropic xenograft model for brain tumor,
U87-MG human malignant glioma cells (16105 cells/10 mL per
mouse brain) were stereotactically implanted into the right
striatum of athymic mice using Just For MiceTM stereotaxic
(Stoelting Co, IL). As an individual therapy, delivery of controls or
Ad-stTRAIL to tumor sites was performed at the indicated times.
BCNU (10 mg/kg) was injected intra-peritoneally followed by
intra-tumoral injections of controls or Ad-stTRAIL. The changes
of established tumor mass were detected by MRI. The survival
profile is expressed as a Kaplan-Meier survival estimate. All the
experiments done on animals were approved by an institutional
review board.
MR imaging
Mice were imaged following anesthesia with ketamin (57 mg/
ml, 15 ml/10 g body weight, injected intra-peritoneally). MRI
examinations were performed on a 1.5-T MRI system (GE Signa
MR/i Hispeed Plus, GE Medical Systems, WI). The volume of
tumor was calculated in T2-weighted axial, coronal and sagittal
images.
Safety evaluation of Ad-stTRAIL
5-week-old male and female rats purchased from Orient Co.,
Ltd. (Seoul, Korea) were given the control (the formulation buffer)
or the modality (36109, 161010 or 361010 viral particles) at the
putamen region of brain: exactly, 3.1 mm right, 0.4 mm front,
6.0 mm deep from the bregma. The same volume (30 ml/head) of
Ad-stTRAIL formulation buffer was used as a vehicle control.
Using 6 male and 6 female rats as an each experimental group,
side effects, such as body weight loss, mortality and/or other
general toxic symptom/appearance, were assessed.
Detection of Ad-stTRAIL DNA in blood plasma, major
organs or brain tissues
The tissues from organs or brain tissues from the virus injection
site were weighed, homogenized and subjected to total DNA
isolation using the QIAmp DNA mini kit (Qiagen). Blood,
obtained from the tail vein or abdominal aorta, was mixed with
heparin (50:1) and centrifuged at 3,000 rpm for 10 minutes to
separate plasma. The total DNA was isolated from the plasma
using QIAmp DNA mini kit. The total tissue or blood DNAs were
subjected to Taqman real time PCR (7900HT real time PCR,
ABI) using the primer sets specifically amplifying the connecting
junction region of between stTRAIL and the viral genome.
Detection of stTRAIL protein
The tissues from the virus injection site were lysed in a buffer
(25 mM Tris (pH 7.4), 50 mM NaCl, 0.5% Na-Deoxycholate, 2%
NP-40, 0.2% SDS, 10% (v/v) protease inhibitor cocktail (Sigma)).
After measuring protein concentration using the Bradford assay kit
(Bio0Rad), lysates were subjected to ELISA. The plates (Immuno
Maxisorp) purchased from Nalge Nunc (Rochester, NY) were
prepared by coating with anti-human TRAIL antibody (1.5 mg/
ml) in a binding solution (50 ml/well, 0.1M Na2HPO4 (pH 9.0))
and blocked with a blocking solution (200 ml/well, 2% BSA in
PBS). The plates were then incubated with lysates or rhTRAIL as
Figure 7. Comparison of Ad-stTRAIL with BCNU in Therapeutic Efficacy. (A) Susceptibility of glioma cells to BCNU in vitro. Cells were
incubated with different concentration of BCNU. After three days, cells were processed for the analysis of cell viability. The results represent the mean
for three separate experiments. The SE bars were omitted, but ,5% at all the data points. (B) Representative MRI after treatment with saline control,
BCNU or Ad-stTRAIL. U87-MG cells (16105 cells/10 ml per mouse brain) were stereotactically implanted into the right striatum of athymic mice (nu/
nu). At day 14 and 18 after tumor implantation, saline or Ad-stTRAIL (161010 VP/head) was delivered intra-tumorally. BCNU (10 mg/kg) was
intraperitoneally delivered at day 14, 16 and 18 after tumor implantation. Tumor growth was monitored by MRI at the indicated times (n = 14 for each
experimental group; total n = 42). (C) Tumor size calculated by MRI shown in (B). (D) TUNEL staining and histology of tumor tissues after treatment
with saline control, BCNU or Ad-stTRAIL. Twenty one days after intracranial implantation of tumors, mice were sacrificed and cryostat sections of brain
were prepared. Cryostat sections were stained with H&E, or subjected to TUNEL staining.
doi:10.1371/journal.pone.0004545.g007
Figure 8. Susceptibility of glioma cells to Ad-stTRAIL, BCNU or Ad-stTRAIL+BCNU combination in vitro. Glioma cells, plated in 24-wells
(16105 cells/well) in complete medium, were incubated with Ad-stTRAIL (0, 10, 50 or 100 MOI), BCNU (50, 100, 100 or 250 mM) or combination of Ad-
stTRAIL and BCNU. Three days after incubation, cells were processed for the analysis of cell viability. The results represent the mean for three separate
experiments. The SE bars were omitted, but ,5% at all the data points.
doi:10.1371/journal.pone.0004545.g008
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a standard. After 1 h incubation at 37uC, the plates were washed
and treated with diluted biotinylated anti-human TRAIL antibody
(100 ml/well, 0.2 mg/ml in incubation buffer) for 1 hr at room
temperature. Following washing, diluted avidin-HRP (100 ml/
well, 1/1000 dilution) was added and incubated for 30 min at
room temperature. ABTS solution (Sigma) was added for color
development and measured by reading absorbance at 405 nm.
TUNEL staining and histology
Twenty one days after intracranial implantation of tumors, mice
were sacrificed and cryostat sections of brain were prepared.
Cryostat sections (6 mm) were air-dried and stained with H&E, or
subjected to TUNEL staining. TUNEL staining was carried out
using the kit DeadEnd Fluorometric TUNEL system from
Promega (Madison, WI). Propidium iodide was used for
counterstaining
Statistical analyses
Analysis of differences was performed using the Wilcoxon rank
sum test.
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Figure 9. Comparison of Ad-stTRAIL+BCNU combination therapy with BCNU individual therapy in therapeutic efficacy. (A) The
schematic drawing for experimental design and MRI analysis (see also Fig. 7B legend). (B) Representative MRI after treatment with saline control, Ad-
stTRAIL individual therapy or Ad-stTRAIL+BCNU combination therapy (n = 15 for each experimental group; total n = 45; see also Fig. 3B legend). (C)
Survival curve. Live animal were counted at the indicated times after treatment as described in (B) (n = 12 for each experimental group; total n = 36).
(D) Median survival. The data described in (C) were analyzed. The range given for survival indicates ‘Anderson 95% CI’ in Kaplan-Meier survival
estimates.
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